156755-37-2

Usage

Uses

1. Used in Pharmaceutical Industry:
BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs targeting specific receptors or enzymes.
2. Used in Chemical Research:
BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)is also utilized in chemical research for studying the properties and reactivity of complex organic molecules. It can serve as a model compound for understanding the behavior of similar structures and their interactions with other molecules.
3. Used in the Synthesis of Fesoteridone:
BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)is an impurity in the synthesis of Fesoteridone (F321300), a muscarinic receptor antagonist used for the treatment of Lower Urinary Tract Symptoms (LUTS). Its presence in the synthesis process may affect the purity and efficacy of the final product, making it important to monitor and control its levels during production.

Upstream product

• 156755-35-0 methyl 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoate 
• 50-00-0 formaldehyd 
• 950773-38-3 R-(-)-[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine 
• 848768-06-9 (R)-3-[2-(benzyloxy)-5-methylphenyl]-N,N-diisopropyl-3-phenylpropan-1-amine 
• 214601-54-4 (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal 
• 1402604-30-1 benzyl desfesoterodine fumarate 
• 209747-05-7 (S)-2-[3-[bis-(1-methylethyl)-amino]-1-phenylpropyl]-4-methylphenol tartrate 
• 124937-52-6 tolterodine tartrate 
• 124937-51-5 (R)-(+)-tolterodine 
• 854306-68-6 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol 
• 389068-22-8 N,N-diisopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropylamine 
• 124936-74-9 N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine 
• 40546-94-9 6-methyl-4-phenyl-3,4-dihydrocoumarin 
• 854306-67-5 methyl 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropionate 

Downstream Products

• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 286930-02-7 fesoterodine 
• 286930-03-8 fesoterodine fumarate 
• 286930-03-8 fesoterodine fumarate 
• 156755-20-3 PNU 200577 l-mandelate salt 
• 1390644-34-4 isobutyric acid 2-((R)-3-diisopropylammonium-1-phenyIpropyl)-4-(hydroxymethyl)phenyl ester (R)-acetoxy(phenyl)acetate 
• 1390644-38-8 (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxylmethyl)phenylmethacrylate mandelate 
• 1390644-37-7 (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxylmethyl)phenyl methacrylate 
• 1390644-50-4 (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl-2-bromo-2-methyl propanoate 
• 1390644-52-6 2-((R)-3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyi)phenyl-3-bromo-2-methyl propanoate 
• 286930-03-8 2-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate 

Relevant academic research and scientific papers

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

PHOSPHOLIPID CONJUGATE

PROBLEM TO BE SOLVED: To provide a compound that suitably interacts with a receptor existing on a cell surface to regulate its activity, to provide a pharmaceutical composition containing the compound, and to provide a method for treating a disease using the compound, and the like. SOLUTION: The above mentioned object is achieved by providing a compound represented by general formula: P-S-L (where, P is a phospholipid moiety; S is a spacer moiety which includes a structure represented by -(PEG)n- wherein n is an integer equal or greater than 5; L is a ligand moiety of a cytoplasmic membrane receptor). SELECTED DRAWING: Figure 3 COPYRIGHT: (C)2016,JPOandINPIT

PROCESS FOR THE PREPARATION OF FESOTERODINE

The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of Fesoterodine from O-benzyl tolterodine.

PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS

The present invention relates to a process for the preparation of fesoterodine or its salts.

DESFESOTERODINE SALTS

The invention relates to substantially pure Desfesoterodine salts, Desfesoterodine salts, solid state forms thereof and pharmaceutical compositions comprising one or more of the Desfesoterodine salts and/or solid state forms thereof.

PROCESSES FOR THE PREPARATION OF FESOTERODINE

The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns.

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES

Provided herein are novel solid state forms of fesoterodine intermediates, (R)-4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzoic acid and (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol, and processes for their preparation thereof. The solid state intermediates are useful for preparing fesoterodine or a pharmaceutically acceptable salt thereof in high purity.

IMPROVED PROCESS FOR DIPHENYLPROPYLAMINE DERIVATIVES

The present invention relates to an improved process for the preparation of biologically active diphenylpropylamine derivatives. The present invention specifically relates to an improved fesoterodine of formula (I) and its pharmaceutically acceptable salts.

Process for the Preparation of Fesoterodine

Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of Fesoterodine or a pharmaceutically acceptable salt thereof in high yield and purity. Disclosed also herein is an improved and industrially advantageous optical resolution method of racemic (±)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine and use thereof for the preparation of Fesoterodine.